Drug Profile
Research programme: monoamine reuptake inhibitors - Sumitomo Pharma America
Alternative Names: SEP 228791Latest Information Update: 22 Jul 2023
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Sumitomo Pharma America
- Class
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Canada (PO)
- 12 Oct 2010 Sepracor is now called Sunovion Pharmaceuticals
- 21 Oct 2009 Preclinical trials in Parkinson's disease in Canada (PO)